Consensus evidence-based guidelines for use of insulin pump therapy in the management of XXXX as per Indian clinical practice.

@entity1 @entity413 @entity2794 @entity6
The use of insulin pump in @entity6 is likely to increase with recent advances in technology. Although the evidence for the superiority of pumps over @entity2794 ( @entity2794 ) is inconsistent, data from accumulating uncontrolled studies indicate greater reductions in glycated haemoglobin in @entity1 switching to continuous subcutaneous insulin infusion (CSII) from @entity2794 therapy. Due to the variability in insulin requirements and sensitivity to CSII pumps, hyperglycaemia in these @entity1 is managed by endocrinologists using individualised therapy. A panel of experts reviewed the existing guidelines and framed recommendations specific to the clinical practice in Indian conditions for use of CSII pumps in the management of hyperglycaemia. Selection of right @entity1 with basic education, motivation and learning skills are essential for successful implementation of CSII therapy with sophisticated programmes. Rapid acting insulin analogues with better pharmacokinetic and pharmacodynamic profile, physical and chemical stability and compatibility with most commercially available insulin pumps are preferred over regular insulin to achieve safe and stable glycaemic control. Further, educating pump users on proper use of CSII pumps, insulin dose adjustments, and handling of accessories are recommended in the current consensus guidelines. Practice of self-monitoring of blood @entity413 and glycated haemoglobin levels are essential to adjust insulin dosage for the management of @entity6 . Use of CSII pumps in special @entity1 populations should be carefully assessed and initiated by endocrinologist. The proposed guidelines can form a basis for use of CSII pumps in the management of hyperglycaemia in the Indian scenario.
